AB — AB Science SA Share News
0.000.00%
Last trade - 00:00- €65.08m
- €73.85m
- €1.17m
Brief: AB Science: Health Canada Has Resumed Review Of New Drug Submission For Masitinib
Brief: AB Science Consolidated Net Loss AT EUR 13,615K
AB Science slides after capital increase
Brief: AB Science Announces Capital Increase For An Amount Of 15 Million Euros
Brief: AB Science Announces Launch Of A Capital Increase
Brief: AB Science Masitinib Patent Granted In Japan
Brief: AB Science Submits Response To EMA Masitinib Regulatory Review
Brief: AB Science: Case Report From Initial Phase I/II Study Evaluating Ab8939
Advisory: Alerts on AB Science SA on financing through issuance of bonds withdrawn
Brief: AB Science Announced Publication Of Masitinib Phase 3 Clinical Trial In Alzheimer’S Disease
Brief: AB Science Announces Drawdown Of Second Tranche Of EUR 6 Mln
Brief: AB Science Receives Approval From FDA To Initiate Phase 3 Study With Masitinib
Brief: AB Science Announces Masitinib Receives Orphan Drug Status For The Treatment Of Amyotrophic Lateral Sclerosis In Switzerland
Brief: AB Science Draws Down First Tranche Of EUR 6 Mln Under Agreement With EIB
Brief: AB Science Receives NOD From Health Canada For Masitinib
Brief: AB Science/Masitinib: U.S FDA Authorizes Start Confirmatory Phase 3 Study In Treatment Of Alzheimer's
Refinitiv Newscasts - UK Day Ahead: Britain's economy probably shrank in August as recession risks mount
AB Science soars after gets green light for Alzheimer's study
French and Benelux stocks-Factors to watch